Total Valuation
Veraxa Biotech has a market cap or net worth of $56.92M. The enterprise value is $303.88M.
Market Cap$56.92M
Enterprise Value$303.88M
Share Statistics
Veraxa Biotech has 25,300,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding25,300,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Veraxa Biotech’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is -0.66%.
Return on Equity (ROE)0.04
Return on Assets (ROA)0.03
Return on Invested Capital (ROIC)-0.66%
Return on Capital Employed (ROCE)>-0.01
Revenue Per Employee0.00
Profits Per Employee1.12M
Employee Count8
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Veraxa Biotech is 50.8. Veraxa Biotech’s PEG ratio is 0.21.
PE Ratio50.8
PS Ratio0.00
PB Ratio1.05
Price to Fair Value1.05
Price to FCF-555.25
Price to Operating Cash Flow-828.42
PEG Ratio0.21
Income Statement
In the last 12 months, Veraxa Biotech had revenue of 0.00 and earned 8.99M in profits. Earnings per share was 0.36.
Revenue0.00
Gross Profit0.00
Operating Income-1.79M
Pretax Income8.99M
Net Income8.99M
EBITDA-1.79M
Earnings Per Share (EPS)0.36
Cash Flow
In the last 12 months, operating cash flow was -412.70K and capital expenditures 0.00, giving a free cash flow of -412.70K billion.
Operating Cash Flow-412.70K
Free Cash Flow-412.70K
Free Cash Flow per Share-0.02
Dividends & Yields
Veraxa Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.06
52-Week Price Change-82.69%
50-Day Moving Average7.24
200-Day Moving Average10.09
Relative Strength Index (RSI)35.13
Average Volume (3m)5.63K
Important Dates
Veraxa Biotech upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Veraxa Biotech as a current ratio of 0.15, with Debt / Equity ratio of 0.00%
Current Ratio0.15
Quick Ratio0.15
Debt to Market Cap0.00
Net Debt to EBITDA0.10
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Veraxa Biotech has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Veraxa Biotech EV to EBITDA ratio is -151.11, with an EV/FCF ratio of -554.87.
EV to Sales0.00
EV to EBITDA-151.11
EV to Free Cash Flow-554.87
EV to Operating Cash Flow-554.87
Balance Sheet
Veraxa Biotech has $32.79K in cash and marketable securities with $0.00 in debt, giving a net cash position of $32.79K billion.
Cash & Marketable Securities$32.79K
Total Debt$0.00
Net Cash$32.79K
Net Cash Per Share<$0.01
Tangible Book Value Per Share$10.15
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Veraxa Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast2.24%